Mupirocin calcium

Research use only, not for human use.

Mupirocin calcium is an antibiotic produced by Pseudomonas fluorescens showed a high level of activity against staphylococci and streptococci and against certain gram-negative bacteria.

Mupirocin calcium is an antibiotic produced by Pseudomonas fluorescens showed a high level of activity against staphylococci and streptococci and against certain gram-negative bacteria.(In Vitro):Mupirocin (BRL-4910A, Pseudomonic acid) calcium hydrate (0-100 μM; 48 h) shows antibacterial effect against staphylococci, streptococci and certain gram-negative bacteria, with MIC values range from 0.06-0.25 μg/mL (MIC50 =0.12 μg/mL, MIC90 =0.25 μg/mL).Mupirocin calcium hydrate is highly bound (95% bound) to human serum protein, thus results in activity inhibition in the presence of human serum.Mupirocin calcium hydrate apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis.Mupirocin calcium hydrate (2% ointment) reduces pro-inflammatory cytokines IL-1β and IL-17 level, decreases tumor necrosis factor-alpha (TNF-α) expression, and increases the leavel of vascular endothelial growth factor (VEGF).Mupirocin calcium hydrate inhibits MS (S. epidermidis ATCC 12228), MR (S. epidermidis (Se56-99)), and VIR (S. epidermidis (Se43-98)) with MICs of 0.25, 1.26, 1.59 mg/L. (In Vivo):MRSA: Meticillin-resistant Staphylococcus aureusMupirocin (BRL-4910A, Pseudomonic acid) calcium is well absorbed after oral and parenteral administration but serum antibiotic concentrations were short-lived as a result of extensive degradation to the antibacterially inactive metabolite, monic acid A.Mupirocin calcium (2% ointment; external administration; twice daily; 3-6 d) decreases the total bacterial loads in the skin lesions with either topical treatment.Mupirocin calcium (2% ointment; external administration; 4 d) alleviates MRSA-infected pressure ulcers in mice.Mupirocin calcium (100 mg/mL; s.c.; 7 d) exerts prevention efficacy against vascular prosthetic graft infection due to Staphylococcus epidermidis.

Mupirocin (BRL-4910A, Pseudomonic acid) calcium hydrate (0-100 μM; 48 h) shows antibacterial effect against staphylococci, streptococci and certain gram-negative bacteria, with MIC values range from 0.06-0.25 μg/mL (MIC50 =0.12 μg/mL, MIC90 =0.25 μg/mL).Mupirocin calcium hydrate is highly bound (95% bound) to human serum protein, thus results in activity inhibition in the presence of human serum.Mupirocin calcium hydrate apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis.Mupirocin calcium hydrate (2% ointment) reduces pro-inflammatory cytokines IL-1β and IL-17 level, decreases tumor necrosis factor-alpha (TNF-α) expression, and increases the leavel of vascular endothelial growth factor (VEGF).Mupirocin calcium hydrate inhibits MS (S. epidermidis ATCC 12228), MR (S. epidermidis (Se56-99)), and VIR (S. epidermidis (Se43-98)) with MICs of 0.25, 1.26, 1.59 mg/L.

MRSA: Meticillin-resistant Staphylococcus aureus.Mupirocin (BRL-4910A, Pseudomonic acid) calcium is well absorbed after oral and parenteral administration but serum antibiotic concentrations were short-lived as a result of extensive degradation to the antibacterially inactive metabolite, monic acid A.Mupirocin calcium (2% ointment; external administration; twice daily; 3-6 d) decreases the total bacterial loads in the skin lesions with either topical treatment.Mupirocin calcium (2% ointment; external administration; 4 d) alleviates MRSA-infected pressure ulcers in mice.Mupirocin calcium (100 mg/mL; s.c.; 7 d) exerts prevention efficacy against vascular prosthetic graft infection due to Staphylococcus epidermidis. Animal Model:MRSA skin infection model in mice (10-12 weeks old)Dosage:2% ointment Administration:External administration; twice daily; 3-6 days Result:Reduced the total bacterial loads in the skin lesions, and decreased by 2.0, 5.1 log10 CFU on day 3 and 6, respectively.Animal Model:Diabetic pressure ulcer mouse model (33.2-39.2 g)Dosage:2% ointment Administration:External administration; 4 days Result: Resulted less superficial mats of bacterial colonies, and improved histopathology evaluation.Animal Model:Adult male Wistar rats (weight 275-325 g)Dosage:Impregnated with 100 μg of mupirocin/mL; segments:1.5 cm *1 cm2 Administration:Subcutaneous implantation; 7 days Result:Resulted in preventing S. epidermidis infection of the graft in a rat model with spontaneously bound to collagen-sealed Dacron grafts.

Mupirocin calcium hydrate

Others

Other Targets

others

——

Secondarily Infected Traumatic Skin Lesions

115074-43-6

1075.34

C52H86CaO18.2H2O

>98% (HPLC)

DMSO:100 mg/mL (92.99 mM)Ethanol:100 mg/mL (92.99 mM)H2O:6 mg/mL (5.58 mM)

[Ca+2].O.O.[O-]C(=O)CCCCCCCCOC(=O)\C=C(/C)C[C@@H]2OC[C@H](C[C@@H]1O[C@H]1[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]2O.[O-]C(=O)CCCCCCCCOC(=O)\C=C(/C)C[C@@H]2OC[C@H](C[C@@H]1O[C@H]1[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]2O

——

(-20℃)

With Ice Pack

≥ 2 years